Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | KYNU | Q16719 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | CTSL | P07711 | 4/20 | 0.49 |
| ▸ | CTSS | P25774 | 4/20 | 0.49 |
| ▸ | CTSK | P43235 | 4/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | CTSB | P07858 | 2/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.47 |
| ▸ | TACR1 | P25103 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2396973 | 0.88 | ALDH1A1 (0.57) | ALDH1A1ALOX15KYNUNPC1RAB9A | |
| SCHEMBL2396971 | 0.88 | ALDH1A1 (0.57) | ALDH1A1ALOX15KYNUNPC1RAB9A | |
| SCHEMBL8569421 | 0.82 | ALDH1A1 (0.65) | ALDH1A1ALOX15CTSLCTSSCTSK | |
| SCHEMBL2406036 | 0.82 | ALDH1A1 (0.65) | ALDH1A1ALOX15CTSLCTSSCTSK | |
| SCHEMBL31725797 | 0.82 | KLK5 (0.53) | ALDH1A1CTSLCTSSCTSKCTSB | |
| SCHEMBL268062 | 0.81 | ALDH1A1 (0.55) | ALDH1A1ALOX15KYNUCTSLCTSS | |
| SCHEMBL268063 | 0.81 | ALDH1A1 (0.55) | ALDH1A1ALOX15KYNUCTSLCTSS | |
| SCHEMBL7151822 | 0.81 | ALDH1A1 (0.74) | ALDH1A1ALOX15KYNUCTSLCTSS | |
| SCHEMBL329686 | 0.81 | ALDH1A1 (0.74) | ALDH1A1ALOX15KYNUCTSLCTSS | |
| SCHEMBL5561541 | 0.81 | ALDH1A1 (0.60) | ALDH1A1ALOX15KYNUCTSLCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060122184-A1 | Cyanomethyl derivatives as cysteine protease inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2006-06-08 | — | — | US | disclosed |
| EP-1569954-A1 | CYANOMETHYL DERIVATIVES AS CYSTEINE PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2005-09-07 | — | — | EP | disclosed |
| WO-2004052921-A1 | CYANOMETHYL DERIVATIVES AS CYSTEINE PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2004-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122184-A1 | Cyanomethyl derivatives as cysteine protease inhibitors | CTSF, CTSB, CTSK | ALDH1A1 3662/4885ALOX15 3388/4885KYNU 1694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.